Active Immunotherapy of Human Melanoma Exploiting the Immunopotentiating Effects of Cyclophosphamide

References

• Old L I. Cancer immunology: the search for specificity. Cancer Res 1981; 41: 361–375
   PubMed Web of Science ®Google Scholar
• Herlyn M, Clark W H., Mastrangelo M J., et al. Specific immune-reactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly-derived human cells. Cancer Res 1980; 40: 3602–3609
   PubMed Web of Science ®Google Scholar
• Mastrangelo M J., Berd D, Maguire H C., Jr. Current condition and prognosis of tumor immunotherapy: A second opinion. Cancer Treat Rep 1984; 68: 207–219
   PubMedGoogle Scholar
• Gershon R K. T cell control of antibody production. Contemp Top Mol Immunol 1974; 3: 1–40
   PubMedGoogle Scholar
• Takei F, Levy J G., Kilburn D G. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice. J Immunol 1976; 116: 288–293
   PubMed Web of Science ®Google Scholar
• Fisher M S., Kripke M L. Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis. Proc Natl Acad Sci (USA) 1977; 74: 1688–1692
   PubMed Web of Science ®Google Scholar
• Hengst J CD, Molcyr M B., Dray S. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 1981; 41: 2163–2167
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Green M I., Sehon A H. Regulation of the immune response to tumor antigens I. Immunosuppressor cells in tumor-bearing hosts. J Immunol 1976; 116: 791–799
   PubMed Web of Science ®Google Scholar
• Mullen C A., Urban J L., Van Waes C, et al. Multiple cancers. Tumor burden permits the outgrowth of other cancers. J Exp Med 1985; 162: 1665–1682
   Google Scholar
• Berendt M J., North R J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980; 151: 69–80
   Google Scholar
• North R J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 55: 1063–1074
   Web of Science ®Google Scholar
• Haar H, Marshall G J., Bierman H, et al. The influence of cyclophosphamide upon neoplastic diseases in man. Cancer Chemother Rep 1960; 6: 41–51
   PubMedGoogle Scholar
• Greenberg P O., Cheever M A., Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lty-1 +,2- lymphocytes. J Exp Med 1981; 154: 952–963
   PubMed Web of Science ®Google Scholar
• Rosenberg S A., Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–1321
   PubMed Web of Science ®Google Scholar
• Glaser M. Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Cell Immunol 1979; 48: 339–345
   PubMed Web of Science ®Google Scholar
• Baldwin R W., Byers V S., Hannant D, et al. Cellular interactions modulating host resistance to tumours. Recent Res Cancer Res 1982; 80: 338–345
   PubMedGoogle Scholar
• Nomi S, Pellis N R., Kahan B D. Antigen-specific therapy of experimental metastases. Cancer 1985; 55: 1296–1302
   PubMed Web of Science ®Google Scholar
• Hawrylko E, Mele C A., Stutman O. Tumor bearer T cells suppress BCG-potentiated antitumor responses JJ. Characteristics of the efferent phase suppressor. Cell Immunol 1982; 66: 139–151
   PubMed Web of Science ®Google Scholar
• Livingston P O., Jones M, DeLeo A B., et al. The serologic response to meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants. J Immunol 1985; 135: 1505–1509
   PubMed Web of Science ®Google Scholar
• Maguire H C., Jr, Ettore V L. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol 1967; 48: 39–42
   PubMed Web of Science ®Google Scholar
• Turk J L., Parker D. Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 1982; 65: 99–113
   PubMed Web of Science ®Google Scholar
• Berd D, Mastrangelo M J., Engstrom P F., et al. Augmentation of the human immune response by cyclophosphamide. Cancer Res 1982; 42: 4862–4866
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire H C., Jr, Mastrangelo M J. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44: 5439–5443
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire H C., Jr, Mastrangelo M J. Impairment of con-canavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res 1984; 44: 1275–1280
   PubMed Web of Science ®Google Scholar
• Berd D, Mastrangelo M J. Effect of low dose cyclophosphamide on the immune system of cancer patient. Reduction of T suppressor function without depletion of the CD8+ subset. Cancer Res 1987; 47: 3317–3321
   Google Scholar
• Berd D, Mastrangelo M J. Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4 +, 2H4+ suppressor-inducer T cells. Cancer Res 1988; 48: 1671–1675
   PubMed Web of Science ®Google Scholar
• Morimoto C, Letvin N L., Rudd C E., et al. The role of the 2H4 molecule in the generation of suppressor function in Con A-activated T cells. J Immunol 1986; 137: 3247–3253
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire H C., Jr, Mastrangelo M J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46: 2572–2577
   PubMed Web of Science ®Google Scholar
• Peters L C., Brandhorst J C., Hanna M G. Preparation of immunother-apeutic autologous tumor cell vaccines from solid tumors. Cancer Res 1979; 39: 1353–1360
   PubMed Web of Science ®Google Scholar
• Old U, Boyse E A., Clarke D A., et al. Antigenic properties of chemically induced tumors. Ann NY Acad Sci 1962; 101: 80–106
   Web of Science ®Google Scholar
• Marchant J. Sarcoma induction in mice by methylcholanthrene. Antigenicity tests of sarcomas induced in thymus grafted and control animals. Br J Cancer 1969; 23: 383–390
   Google Scholar
• Sahasrabudhe D M., deKernion J B., Pontes J E., et al. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Resp Modif 1986; 5: 581–594
   PubMedGoogle Scholar